Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Investment Research • Oct 26, 2026

Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its third quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (“SEC”). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the third quarter 2026, which will be.

Business Wire • Oct 19, 2026

Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon reports positive interim Phase 3 results for MIUDELLA®, a hormone-free IUD, through 6 years of use with no new safety signals.

Business Wire • Oct 16, 2026

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.

Zacks Investment Research • Oct 14, 2026

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock

Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Investment Research • Oct 2, 2026

Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to unveil first large-scale real-world effectiveness analyses of VTAMA (tapinarof) cream, 1% in patients with eczema at Fall Clinical.

Business Wire • Oct 1, 2026

Is Trending Stock Organon & Co. (OGN) a Buy Now?

Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks Investment Research • Sep 21, 2026

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces FDA accepts MIUDELLA® sNDA for review, seeking to extend approved hormone-free IUD use from 3 to 6 years in the U.S.

Business Wire • Sep 14, 2026

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Investment Research • Sep 8, 2026

National Can-RISE Study to Help Close Critical Gaps in Menopause Research

TORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Women's Health Collective Canada (WHCC) and the Partnership for Women's Health Research Canada (PWHR), in partnership with GreenShield and supported by a charitable grant from Organon, have launched the Researching Information, Support, and Equity During the Menopause Transition in Canada (Can-RISE) Study. As the first national investigator-led study focused on Canadian women's experiences of menopause and the menopausal transition, Can-RISE is led by PWHR with funding support from WHCC.

GlobeNewsWire • Aug 27, 2026